TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Major treatment effect (MTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Toxicity of Romidepsin
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Romidepsin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of syndesmotic reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Functional outcome measured by AAOS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Extent of absorption in SUV standard uptake value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of acute inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STOP-BANG questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of complications during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: incidence of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Monitoring of bone free flaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post treatment weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of focal lesions ≥ 5mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Visual Analogue Scale for Pain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Visual Analogue Scale for Nausea Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between hyperintensity lesions in FLAIR MRI and demyelination in amyloid PET image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Muscle Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood carnitine level (free, total, and acylcarnitine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum tolerated dose of bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate of the combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Failures
Endpoint domain: Adverse events/effects
Primary endpoint: Termination of SVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary Site Complete Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (Complete Plus Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects with true positive (malignant) breast lesions confirmed by biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects with false positive (benign) breast lesions confirmed by biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Bowel related quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pediatric Behavior Adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Referral to knee joint replacement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Symptomatic intracerebral hemorrhage (ICH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recanalization of primary arterial occlusive lesion (AOL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive predictive value of PASE score ≥ 44 for psoriatic arthritis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline Body fat percentage at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Muscle strength at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline exercise self-efficacy at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: decrease in physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Selective fat malabsorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relative change in Gas Chromatography Ion Mobility Spectra (GC-IMS) of VOC's
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in normal tissue and tumour cell free DNA (cfDNA) in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True rectal wall delivered radiation dose compared to planned dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference of indocyanine in mammalian tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative change of cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mean early diastolic mitral annular velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Knee Kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Fugl-Meyer Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unacceptable toxicity or tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Coagulability measurement with device vs. Prothrombin time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Coagulability measurement with device vs. anti-Xa activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Coagulability measurement with device vs. PTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in snoring levels greater than 40dB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale (VAS) snoring scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete dissolution of thrombus in left atrium or left atrial appendage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: stable blood levels of TMC 435
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stable blood levels of escitalopram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of deaths
Endpoint domain: Mortality/survival
Primary endpoint: Radiographic Progression Free Survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in suicide rates
Endpoint domain: Mortality/survival
Primary endpoint: response rate of the treated lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-epithelization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral health impact profile (OHIP-14)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Graft dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model for end-stage liver disease (MELD score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in spider phobia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in social phobia symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Patients in Arm I with Complete Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Patients in Arm II that Obtain to Resectable Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients Who Were Able to Complete Treatment Delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain and discomfort during and after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological Stress and Adaptation at work Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of H. pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Depression Scale for Children (CES-DC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Esteem Scale (RSES)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality-of-life Inventory (PedsQL v. 4.0)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Distance walked during the six minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consent competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consent disclosure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consent understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consent voluntariness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Use of social support and information seeking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Experienced harms and benefits
Endpoint domain: Adverse events/effects
Primary endpoint: Experiences with HIV testing and PrEP adherence technologies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average difference in area under the curve of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of participants given a recommendation to stop taking aspirin
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants correctly identifying national organizations with perioperative aspirin recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of participants correctly answering questions about platelet rebound effect
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Energy expenditure in kcal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exercise persistence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in the Degree of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastrocnemius muscle-tendon length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Achilles tendon length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Passive range of motion of the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent of patients presenting no hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve for oxygen saturation (SpO2%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in Lower Urinary Tract Symptoms (LUTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence or absence of ischemic complications to the bladder, rectum, or other pelvic structures
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3 and 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: PaO2/FiO2 Ratio Less Than or Equal to 55
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiac Index Less Than or Equal to 2.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Motor Milestones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of osteoporotic fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Expression of RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarkers of cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in polyphenol absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PTCD CheckList (PCL) total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Maximal Mouth Opening Range of Motion (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain with Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Function with Jaw Functional Limitation Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Oxford Handicap Scale (OHS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence and frequency of adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of infantile hemangioma
Endpoint domain: Mortality/survival
Primary endpoint: Bladder pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Meningococcal Serum Bactericidal Antibodies/Assay (rSBA) Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MRI Brain SWI and FLAIR Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Illness Perception Questionnaire Revised (IPQR)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EPP-Specific Tool
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Secondary acquired infection (SAI)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects With Detectable Serum HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-Inflammatory Effects of Paricalcitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Endothelial Protectant Effects of Paricalcitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective treatment outcomes of incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: four-fold increase in HI titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects With Treatment-related Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetes Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in biomarker expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent malapposed struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: change from baseline in electrocardiogram (ECG) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chinese symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropathic Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of neonates who acquired infection
Endpoint domain: Adverse events/effects
Primary endpoint: THC and metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: performance on neurocognitive tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative change in percent predicted FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immune cells activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Necessary force of CP to occlude the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change on Bite Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sebum excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stool microbiome diversity via stool sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients achieving HR-CTV dose to 90% (D90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Satisfied With Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Improvement in Working Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate antimicrobial treatment for nosocomial infection
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of single ascending oral doses of INX-08189
Endpoint domain: Adverse events/effects
Primary endpoint: Prevention of HEV diseases
Endpoint domain: Mortality/survival
Primary endpoint: Changes in mean amplitude of glycemic excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in standard deviation of blood glucose (SDBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endothelium-dependent skin microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Non-fatal Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Non-fatal Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Death Due to Vascular Causes
Endpoint domain: Mortality/survival
Primary endpoint: Restoration Percent Success at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ibsilateral locoregional tumor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic accuracy for detecting atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Clinical Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aversive Reactions to Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GTPase activity inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of BOS using MRI imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isometric strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop Test
Endpoint domain: Cognitive functioning
Primary endpoint: Muscle Damage Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants With Pressure Ulcer
Endpoint domain: Adverse events/effects
Primary endpoint: Dental implant linear measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reaching LDL-C Goal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean keratometry in diopters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of drug administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Crying score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients receiving appropriate oral anticoagulant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite cardiovascular disease outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes